HK Inno.N is now responsible for the domestic distribution of Tamiflu capsules, following its success with the antiviral drug Xofluza.

With Tamiflu generating annual sales of approximately 15 billion KRW, this move is expected to significantly expand HK Inno.N’s market presence.

According to industry sources on the 15th, HK Inno.N issued a notice to its clients, announcing that it began distributing Roche Korea's Tamiflu capsules (30/45/75mg) as of the 14th.

Tamiflu is synonymous with influenza antiviral treatments. While sales dipped during the peak of the COVID-19 pandemic in 2020 and 2021, they rebounded sharply last year as influenza cases surged. According to U-BIST data, Tamiflu's total outpatient prescription revenue reached 15 billion KRW in 2023.

Previously, Tamiflu’s domestic distribution had been managed by Chong Kun Dang since 2012. However, following the expiration of the agreement last year, Roche began seeking a new distribution partner in Korea.

Last year, HK Inno.N signed an exclusive distribution and co-marketing agreement with Roche Korea for the antiviral drug Xofluza (baloxavir marboxil). Under this agreement, HK Inno.N has been handling Xofluza’s distribution while collaborating with Roche on marketing and sales efforts.

Xofluza stands out as a groundbreaking oral influenza treatment, requiring only a single dose compared to the traditional five-day course of treatment. Developed as the first new influenza antiviral drug in 20 years, Xofluza has yet to make a significant impact in Korea due to its non-reimbursed status. However, experts anticipate it could capture a substantial share of Tamiflu's market if it gains reimbursement approval.

By entrusting both Xofluza and Tamiflu distribution to HK Inno.N, Roche has demonstrated confidence in its new Korean partner. HK Inno.N appears to be solidifying its position as Roche’s preferred partner in Korea, following in Chong Kun Dang’s footsteps.